448 related articles for article (PubMed ID: 34888246)
1. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu LF; Lan HR; Huang D; Li XM; Jin KT
Front Oncol; 2021; 11():769305. PubMed ID: 34888246
[TBL] [Abstract][Full Text] [Related]
2. Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution - A role for immunotherapy.
Tieng FYF; Lee LH; Ab Mutalib NS
Front Immunol; 2022; 13():959705. PubMed ID: 36032085
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
4. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
7. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
11. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
12. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
14. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
Yu I; Dakwar A; Takabe K
Cells; 2023 Jan; 12(2):. PubMed ID: 36672193
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and immunoevasion of colorectal cancer.
Al Zein M; Boukhdoud M; Shammaa H; Mouslem H; El Ayoubi LM; Iratni R; Issa K; Khachab M; Assi HI; Sahebkar A; Eid AH
Drug Discov Today; 2023 Sep; 28(9):103669. PubMed ID: 37328052
[TBL] [Abstract][Full Text] [Related]
17. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
Tolba MF
Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
[TBL] [Abstract][Full Text] [Related]
18. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
19. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
